What is Xeris Biopharma Holdings, Inc. (XERS) stock price today?

Xeris Biopharma Holdings, Inc. (XERS) is currently trading at $10.48, up 2.85% today.

What is XERS P/E ratio?

Xeris Biopharma Holdings, Inc.'s P/E ratio is -104.33. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is XERS return on equity (ROE)?

Xeris Biopharma Holdings, Inc.'s return on equity (ROE) is -426.33%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Xeris Biopharma Holdings, Inc.'s market cap?

Xeris Biopharma Holdings, Inc. has a market capitalization of $1.81B.

NASDAQ · Biotechnology

Xeris Biopharma Holdings, Inc. (XERS) Stock

$10.48 +2.85% NASDAQ: XERS Healthcare

Valuation

Metric	Value
Price	$10.48
Market Cap	$1.81B
P/E Ratio	-104.33
P/B Ratio	-179.85
P/S Ratio	5.21
EPS (TTM)	$0.07
52-Week High	$11.33
52-Week Low	$5.25
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-426.33%
ROA	-4.17%
ROCE	16.46%
Gross Margin	81.59%
Operating Margin	11.40%
Net Margin	-5.12%
Debt/Equity	-29.74
Current Ratio	2.18

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$50.0M	$110.0M	$164.0M	$203.0M	$292.0M
Operating Profit	$-115.0M	$-82.0M	$-44.0M	$-34.0M	$25.0M
Net Profit	$-123.0M	$-95.0M	$-62.0M	$-55.0M	$1.0M
EPS	$-1.55	$-0.70	$-0.45	$-0.37	$0.00
Op Margin	-232.2%	-74.3%	-26.9%	-16.6%	8.5%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$304.0M	$345.0M	$323.0M	$323.0M	$384.0M
Total Liabilities	$209.0M	$299.0M	$329.0M	$353.0M	$370.0M
Cash	$67.0M	$122.0M	$67.0M	$72.0M	$111.0M
Borrowings	$88.0M	$198.0M	$229.0M	$271.0M	$38.0M

Latest News

Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last? Zacks · Jul 8, 2026 Xeris Biopharma Holdings Insider Sold Shares Worth $383,176, According to a Recent SEC Filing MT Newswires · Jul 7, 2026 CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire · Jul 3, 2026 Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity? Insider Monkey · Jun 30, 2026 Xeris Biopharma Appoints CEO John Shannon Board Chair MT Newswires · Jun 30, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-96.0M	$-103.0M	$-47.0M	$-37.0M	$29.0M
Investing Cash Flow	$97.0M	$34.0M	$-8.0M	$4.0M	$-1.0M
Financing Cash Flow	$-1.0M	$-6.0M	$-2.0M	$-2.0M	$-11.0M
Net Cash Flow	$30.0M	$59.0M	$-55.0M	$4.0M	$39.0M
Free Cash Flow	$-97.0M	$-103.0M	$-49.0M	$-38.0M	$28.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.01
EV / EBITDA	116.77
FCF Yield	3.17%
Quick Ratio	1.02
Interest Coverage	1.30
Return 1Y	64.26%
Return 3Y	233.73%
Return 5Y	134.56%

Ownership

Insiders Held3.38%

Institutions Held62.61%

Institutions Float Held64.80%

Institutional Holder	Shares	Report Date
Blackrock Inc.	12,945,785	2026-03-31
Shaw D.E. & Co., Inc.	7,788,811	2026-03-31
Vanguard Capital Management LLC	6,980,882	2026-03-31
State Street Corporation	4,658,174	2026-03-31
Geode Capital Management, LLC	4,290,629	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ASNDAscendis Pharma A/S - Ordinary Share	$229.23	+2.94%	16.85	$14.24B	0.00%
CORTCorcept Therapeutics Incorporated	$121.19	+2.24%	221.60	$13.10B	0.00%
ETONEton Pharmaceuticals, Inc.	$55.21	+0.84%	119.05	$1.51B	0.00%
GHRSGH Research PLC	$21.11	+3.23%	-22.71	$1.45B	0.00%
MBXMBX Biosciences, Inc.	$53.24	-0.02%	-24.38	$2.53B	0.00%

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. is led by CEO John Shannon, publicly traded since 2018.

Xeris Biopharma Holdings, Inc. (XERS) stock trades at $10.48 with a market capitalization of $1.81B. The stock is valued at a price-to-earnings (P/E) ratio of -104.33, price-to-book of -179.85, price-to-sales of 5.21. Over the past 52 weeks the stock has ranged between $5.25 and $11.33, and currently trades 7.5% below its 52-week high.

On profitability, Xeris Biopharma Holdings, Inc. generates a return on equity (ROE) of -426.33%, return on capital employed of 16.46%, an operating margin of 11.40%, a net profit margin of -5.12%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides